A citation-based method for searching scientific literature

Su-Jin Kim, Cuilan Nian, Doris J Doudet, Christopher H S McIntosh. Diabetes 2009
Times Cited: 76



Kalpit A Vora, Gene Porter, Roche Peng, Yan Cui, Kellyann Pryor, George Eiermann, Dennis M Zaller. BMC Immunol 2009
Times Cited: 38




List of shared articles



Times cited


The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].
Theodosios D Filippatos, Vasilios G Athyros, Moses S Elisaf. Expert Opin Drug Metab Toxicol 2014
34

Dipeptidyl peptidase in autoimmune pathophysiology.
Kei Ohnuma, Osamu Hosono, Nam H Dang, Chikao Morimoto. Adv Clin Chem 2011
50



Role of pancreatic β-cell death and inflammation in diabetes.
W Quan, E-K Jo, M-S Lee. Diabetes Obes Metab 2013
50

Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions.
Shiying Shao, QinQin Xu, Xuefeng Yu, Ruping Pan, Yong Chen. Pharmacol Ther 2020
38

Soluble CD26 / dipeptidyl peptidase IV enhances human lymphocyte proliferation in vitro independent of dipeptidyl peptidase enzyme activity and adenosine deaminase binding.
D M T Yu, L Slaitini, V Gysbers, A G M Riekhoff, T Kähne, H M Knott, I De Meester, C A Abbott, G W McCaughan, M D Gorrell. Scand J Immunol 2011
43

The new insights from DPP-4 inhibitors: their potential immune modulatory function in autoimmune diabetes.
Yunjuan Zhao, Lin Yang, Xiangbing Wang, Zhiguang Zhou. Diabetes Metab Res Rev 2014
39